Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for DEFERASIROX
- Thalidomide and Hydroxyurea Combination in β-Thalassemia Patients
- Low Dose Iron Chelation as TReatment of Oxidative Damage in Sickle Cell Disease
- Phase 2a Pilot Study of NBMI Treatment in Patients With Beta Thalassemia Major, Requiring Iron Chelation
- Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS
- Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation
- Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents
- Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis
- A Two-year Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis.
- Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet
- The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major
- Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome
- The Deferasirox-calcium-vitamin D3 Therapy for Postmenopausal Osteoporosis (PMOP)
- Study of The Therapeutic Benefits of Al-hijamah in Children With Beta Thalassemia Major
- Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation
- A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.
- Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients
- Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients
- Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload
- The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens
- Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65
- Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)
- Clinical Trial of Deferasirox Combination Treatment With Deferiprone In Thalassaemia Patients
- Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.
- Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
- Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia
- Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)
- Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
- Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses
- Treatment of Iron Overload Requiring Chelation Therapy
- Renal Function Among Thalassemia Patients Treated by a Oral Chelator Deferasirox
- Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
- Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.
- Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients
- Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients
- Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC
- An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old
- A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS
- Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia
- Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia
- Post Hematopoietic Stem Cell Transplantation
- Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload
- Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload
- Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea
- Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox
- Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload
- Effects of Iron Loading and Iron Chelation Therapy on Innate Immunity During Human Endotoxemia
- Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload
- Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study
- Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda
- The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis
- Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
- Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload
- This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.
- Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
- Exjade-Early-Trial
- Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study
- Clinical Importance of Treating Iron Overload in Sickle Cell Disease
- Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study
- Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload
- Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec
- Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study
- Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food
- Pilot Study for Patients With Poor Response to Deferasirox
- Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both
- Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload
- Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload
- Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
- Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
- Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload
- Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda
- Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload
- Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload
- Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload
- Safety, Tolerability, and Efficacy of Deferasirox in MDS
- ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
- Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load
- Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment
- Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.
- Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam
- The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
- Effect of a Potent Inducer Rifampicin on the Pharmacokinetics of Deferasirox in Healthy Volunteers
- Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis
- A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.
- Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload
- Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients
- Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload
- A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload
- Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
- An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload
- A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis
- Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients
- Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
- Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients
- Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions
- Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias
- Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions
Clinical trials list
click for details